Navigation Links
Fontus Pharmaceuticals Acquires Nephrology and Endocrinology Drug from Roche Laboratories Inc.
Date:6/16/2008

Launches Nephrology and Endocrinology Product Line

PARSIPPANY, N.J., June 16 /PRNewswire/ -- Fontus Pharmaceuticals, Inc., a specialty pharmaceutical company focused on nephrology and endocrinology, announced today that it has acquired ROCALTROL(R) (calcitriol) from Roche Laboratories Inc. ROCALTROL is a vitamin D analog prescribed by nephrologists for the management of hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (CRF) and by endocrinologists for the management of hypocalcemia in patients with post-surgical hypoparathyroidism, idiopathic hypoparathyroidism and pseudohypoparathyroidism.

About ROCALTROL(R) (calcitriol)

ROCALTROL, available as capsules and as an oral solution, is the most potent metabolite of vitamin D available and is active in regulating the absorption of calcium from the gastrointestinal tract and its utilization in the body. The calcitriol in ROCALTROL is believed to be the active hormone which exerts vitamin D activity in the body. ROCALTROL improves calcium absorption in patients who have severe vitamin D deficiencies commonly associated with CRF, chronic kidney disease (CKD), end-stage renal disease (ESRD) or primary hypothyroidism.

ROCALTROL therapy should always be started at the lowest possible dose and should not be increased without careful monitoring of serum calcium. In order to avoid hypercalcemia and related conditions, the optimal daily dose of ROCALTROL must be carefully determined for each patient. The safety and effectiveness of ROCALTROL in pediatric predialysis patients is based on evidence from adequate and well controlled studies of ROCALTROL in adults with predialysis chronic renal failure and additional supportive data from non-placebo controlled studies in pediatric patients. Specific doses of ROCALTROL are recommended for pediatric predialysis patients. These and other precautions and warnings may be found in the package insert for ROCALTROL.

About Fontus Pharmaceuticals

Fontus Pharmaceuticals, Inc. ("Fontus") is a specialty pharmaceutical company distinguished by its strategy to acquire and market FDA-approved products used in the fields of nephrology and endocrinology. Fontus focuses on mature products with widely accepted clinical value and brand loyalty. Fontus re-invigorates promotion and in some cases reformulates products to optimize clinical benefit. Fontus is the second new specialty pharmaceutical company to be formed with an investment from the private equity fund, Konanda Pharma Fund I, L.P. For more information, please visit http://www.fontuspharma.com.

About Konanda Pharma Fund I, L.P.

Konanda Pharma Fund I, L.P. is a private equity fund that founds and invests in portfolio companies that acquire mature prescription drug brands that offer important therapeutic benefits. For more information, please visit http://www.konanda.com.


'/>"/>
SOURCE Fontus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Celator(R) Pharmaceuticals to Present at 2008 BIO International Convention
2. Scimitar Equity, LLC Initiates Coverage Review of VioQuest Pharmaceuticals, Inc.
3. GlaxoSmithKline and Mpex Pharmaceuticals Form Alliance to Develop Novel Efflux Pump Inhibitors for Use Against Serious Gram-Negative Infections
4. Raptor Pharmaceuticals Corp. To Present at BIO 2008 International Convention
5. Jazz Pharmaceuticals Files Form S-3 Registration Statements
6. Quark Pharmaceuticals to Participate in 9th Annual Beyond Genome Conference
7. Merrimack Pharmaceuticals Raises $60 Million in Private Financing
8. The Leukemia & Lymphoma Society and Provid Pharmaceuticals Announce Collaboration on Treatment for Acute Myelogenous Leukemia
9. Diffusion Pharmaceuticals Announces Addition of Mark T. Giles to its Board of Directors
10. Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals
11. Amira Pharmaceuticals Hires Industry Veteran for CFO Position
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... ... monitoring solutions, today announced the hire of Dr. Sigmund “Sig” Floyd as Vice ... applications, strategic partnerships and joint development activities. , “Dr. Floyd’s career has spanned ...
(Date:3/22/2017)... March 22, 2017  UBM and the Massachusetts ... their extended partnership and the third annual Massachusetts Medtech ... the 21 st Annual MassMEDIC Conference held ... May 3-4, 2017. MassMEDIC will ... (ADVAMED) President and CEO, Scott Whitaker , ...
(Date:3/22/2017)... , March 22, 2017 The ... states a research report by Transparency Market Research (TMR). ... Amgen Inc., and AbbVie Inc., accounted for a share ... prominent players in this market are focusing aggressively on ... portfolio, which is likely to lead to market consolidation ...
(Date:3/22/2017)... , March 22, 2017   VWR ... provider of product and service solutions to ... it has acquired EPL Archives, Inc., an ... across the entire regulated product research, development ... document storage and ancillary services. EPL Archives ...
Breaking Biology Technology:
(Date:3/23/2017)... 2017 The report "Gesture Recognition and Touchless Sensing Market ... - Global Forecast to 2022", published by MarketsandMarkets, the market is expected to ... between 2017 and 2022. Continue Reading ... ... ...
(Date:3/22/2017)... 21, 2017   Neurotechnology , a provider ... today announced the release of the SentiVeillance ... improved facial recognition using up to 10 surveillance, ... computer. The new version uses deep neural-network-based facial ... it utilizes a Graphing Processing Unit (GPU) for ...
(Date:3/22/2017)... -- Vigilant Solutions , a vehicle location and ... today the appointment of retired FBI special agent ... development. Mr. Sheridan brings more than 21 ... on the aviation transportation sector, to his new role ... served as the Aviation Liaison Agent Coordinator (ALAC) in ...
Breaking Biology News(10 mins):